# ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

> **NCT04561245** · PHASE1 · COMPLETED · sponsor: **Altimmune, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Obesity
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** ALT-801
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04561245
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04561245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04561245, "ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04561245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*